Introduction {#sec1}
============

Colorectal cancer (CRC) is a critical public health problem, which is the third most commonly diagnosed cancer and the third common cause of cancer deaths in both males and females. There were 134490 new CRC cases and 49190 mortalities by estimation in the United States in 2016 \[[@B1]\]. The colorectal carcinogenesis is a complex multistep progress (a benign adenomatous polyp -- an advanced adenoma with high-grade dysplasia -- an invasive cancer) with altered expression of oncogenes, tumor suppressor genes and DNA repair genes \[[@B2]\]. However, the etiology of CRC is still unclear. It is known to all that CRC is a multifactorial and multigenic disease, and is influenced by environment conditions, diet habits, genetic mutations, and *Escherichia coli* infection \[[@B3],[@B4]\]. With increasing numbers of studies, more gene polymorphisms were found to contribute to CRC \[[@B5]\]. These single nucleotide polymorphisms (SNPs) can be used as makers for improving cancer diagnosis and determination of treatment plans \[[@B6]\].

As a key enzyme and an important regulator for the metabolism of folate/vitamin B~9~, methylenetetrahydrofolate reductase (*MTHFR*) catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate \[[@B7]\]. Simultaneously, the 5-methyltetrahydrofolate is the main circulatory form of folate in the body and provides a methyl group to convert the amino acid homocysteine into methionine, which is the precursor of S-adenosylmethionine (SAM). SAM is the major methyl donor in the cell and takes part in DNA methylation \[[@B8]\]. Therefore, *MTHFR* not only plays a role in making proteins and other important compounds, but also is an important factor in DNA methylation, synthesis, and repair \[[@B9]\]. The enzyme is encoded by the *MTHFR* gene located on the short arm of chromosome 1-1p36.3 \[[@B10]\]. Previously, several mutations of *MTHFR* gene have been found and *MTHFR* C677T (rs1801133) is the most common type amongst them. *MTHFR* C677T represents an alanine-to-valine substitution at nucleotide position 677 in exon 4 resulting in thermolability and concurrent decreased activity of the enzyme \[[@B11],[@B12]\]. *MTHFR* gene mutations lead to *MTHFR* enzyme dificiency, low plasma folate levels, hyperhomocysteinemia \[[@B13],[@B14]\] and certain diseases such as cardiovascular disease, pregnancy complications, neural defect, and several cancers including CRC \[[@B15]--[@B21]\]. With a growing number of studies conducted to explore such association, we hypothesized that rs1801133 was likely to relate to colorectal carcinogenesis.

Many researchers have carried out a large number of studies to examine the potential association between *MTHFR* C677T polymorphism and CRC susceptibility. But, the results are still inconclusive so far. Thus, the aim of this meta-analysis including all available case--control studies was to investigate a more reliable association.

Materials and methods {#sec2}
=====================

We searched several databases including PubMed, Embase, Web of Science, and CNKI database for published studies about exploring the association between *MTHFR* C677T polymorphism and CRC susceptibility till May 1, 2017. The search strategy included listed key words: 'methylenetetrahydrofolate reductase', '*MTHFR* polymorphism', 'C677T', 'rs1801133', and 'risk or susceptibility' and 'colorectal or colon or rectal cancer'. Furthermore, we manually searched the reference lists of clinical trials and former meta-analyses for more relevant studies. When duplicate data appeared in different publications, this meta-analysis only adopted the most recent study or the study with the most complete information. The meta-analysis was on the basis of the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) \[[@B22]\]. The eligible studies needed to accord with the following inclusion criteria: (i) case--control studies; (ii) the language was not restricted to English; (iii) investigating the association between *MTHFR* C677T polymorphism and CRC susceptibility; (iv) offering enough raw data to calculate odds ratio (OR) with 95% confidence interval (CI). Additionally, exclusion criteria were as follows: (i) non-case--control studies; (ii) lack of sufficient data for calculating genotype frequency; (iii) case--control studies about examining the relationship between *MTHFR* C677T polymorphism and colorectal adenoma; (iv) duplicated publications.

Data extraction {#sec2-1}
---------------

In order to guarantee the accuracy of extracted information, two authors individually reviewed each publication and extracted useful data on the basis of the inclusion criteria listed above. When disagreements arose in the course of data extraction, discussion was carried out with other authors until the agreements were reached. The following information were extracted from each study to accomplish a standardized sheet: first author's name, year of publication, ethnicity of population, source of controls (hospital based or population based), genotyping method, sample size of cases and controls, genotype frequency of rs1801133 in cases and controls, and the results of the Hardy--Weinberg equilibrium (HWE) test.

Statistical analysis {#sec2-2}
--------------------

The relationship between *MTHFR* C677T polymorphism and CRC susceptibility was analyzed by using five models including the dominant model (CT + TT compared with CC), the recessive model (TT compared with CT + CC), the homozygous model (TT compared with CC), the heterozygous model (CT compared with CC), and the allele model (T compared with C). The goodness-of-fit *χ*^2^ test was conducted to evaluate the HWE in control groups and *P*\<0.05 was regarded as significant disequilibrium \[[@B23]\]. Stratified analysis were performed by ethnicity, source of controls, and genotyping method. Besides, the pooled OR together with 95% CI were measured to bring out the strength of such association. The fixed effects model (Mantel--Haenszel method) and the random effects model (Dersimonian--Laird method) were selected to use based on heterogeneity in the meta-analysis. If there was no or little heterogeneity, the fixed effects model was used; otherwise, the random effects model was used. Due to only particular genotypes extracted in several studies, the dominant model analysis were carried out for all the included studies \[[@B84]\]. Galbraith graph was performed to explore the impossible cause of heterogeneity \[[@B24]\]. A sensitivity analysis was conducted to assess the stability of the results. Begg's funnel plot was performed for potential publication bias and Egger's linear regression test was executed to assess funnel plot asymmetry statistically. If *P*\<0.05, publication bias existed \[[@B25]\]. All statistical data analyses were carried out by using Stata software (version 12.0, StataCorp LP, College Station, TX, U.S.A.).

Results {#sec3}
=======

Characteristics of the studies {#sec3-1}
------------------------------

According to PRISMA-P, this meta-analysis contained 37049 cases and 52444 controls that were combined from 87 publications with 91 eligible case--control studies to examine the relationship between rs1801133 polymorphism and CRC risks \[[@B26]--[@B112]\]. The literature retrieval and selection process are shown in the flowchart in [Figure 1](#F1){ref-type="fig"}. Detailed information of each study were listed in [Table 1](#T1){ref-type="table"}. The distribution of genotypes in controls was consistent with HWE except 15 studies \[[@B33]--[@B35],[@B37],[@B39],[@B47],[@B63],[@B71],[@B76],[@B80],[@B87],[@B88],[@B106],[@B110],[@B111]\]. In these studies, four ethnicities of population were included: Asian, Caucasian, African, and mixed ethnic group. Nine genotyping methods were applied: PCR-restriction fragment length polymorphism (PCR-RFLP), real-time PCR (RT-PCR), PCR-single strand conformation polymorphism (PCR-SSCP), methylation-specific PCR (MS-PCR), mutagenically separated PCR (MSP), MALDI-TOF-MS, Taqman, MassARRAY, and Sequenom. Depending on different sources of control, population-based and hospital-based control groups were distinguished in all the included studies.

![Flowchart of literature search and selection process](bsr-37-bsr20170917-g1){#F1}

###### Characteristics of individual studies included in the meta-analysis

  MTHFR rs1801133                                                                                                              Case (*n*)   Control (*n*)                                           
  ----------------- ------------------------------------ --------------- -------- ------------------------ --------- --------- ------------ --------------- --------- --------- --------- --------- -------
  2016              Haerian \[[@B26]\]                   Asian           HB       Taqman                   1123      1298      607          421             95        667       523       108       Y
  2015              Kim \[[@B27]\]                       Asian           PB       PCR-RFLP                 477       514       159          248             70        172       265       77        Y
  2014              Rai \[[@B28]\]                       Asian           PB       PCR-RFLP                 155       294       137          17              1         261       31        2         Y
  **2014**          **Ozen** \[[@B29]\]                  **Caucasian**   **PB**   **RT-PCR**               **86**    **212**   **36**       **32**          **18**    **207**   **5**     **0**     **Y**
  **2013**          **Ashmore** \[[@B30]\]               **Caucasian**   **PB**   **RT-PCR**               **625**   **603**   **241**      **309**         **75**    **263**   **259**   **81**    **Y**
  **2013**          **Delgado- Plasencia** \[[@B31]\]    **Caucasian**   **HB**   **PCR-RFLP**             **50**    **103**   **32**       **16**          **2**     **44**    **50**    **9**     **Y**
  2013              Yousef \[[@B32]\]                    Asian           PB       PCR-RFLP                 128       116       79           45              4         59        45        12        Y
  2012              Lee \[[@B33]\]                       Caucasian       PB       Taqman                   531       1004      250          229             52        464       391       149       N
  2012              Promthet \[[@B34]\]                  Asian           HB       PCR-RFLP                 112       242       93           18              1         185       49        8         N
  2012              Kim \[[@B35]\]                       Asian           HB       Taqman                   787       656       265          393             129       205       289       162       N
  2012              Yin \[[@B36]\]                       Asian           HB       RT-PCR                   370       370       124          167             79        139       178       53        Y
  2011              Sameer \[[@B37]\]                    Asian           PB       PCR-RFLP                 86        160       59           18              9         121       27        12        N
  2011              Vossen \[[@B38]\]                    Caucasian       PB       Taqman                   1762      1811      737          823             202       795       807       209       Y
  2011              Kang \[[@B39]\]                      Asian           PB       PCR-RFLP                 255       448       87           134             34        145       238       65        N
  **2011**          **Zhu** \[[@B40]\]                   **Asian**       **PB**   **PCR-RFLP**             **86**    **100**   **29**       **42**          **15**    **49**    **41**    **10**    **Y**
  2011              Pardini \[[@B41]\]                   Caucasian       HB       PCR-RFLP                 666       1376      317          307             42        613       627       136       Y
  2011              Kim \[[@B42]\]                       Asian           HB       MSP                      67        53        30           30              7         15        21        17        Y
  **2011**          **Prasad** \[[@B43]\]                **Asian**       **PB**   **PCR-RFLP**             **110**   **241**   **97**       **12**          **1**     **228**   **12**    **1**     **Y**
  2011              Li \[[@B44]\]                        Asian           PB       PCR-RFLP                 137       145       68           54              15        55        64        26        Y
  2011              Jokic \[[@B45]\]                     Caucasian       PB       Taqman                   300       300       139          130             31        142       130       28        Y
  2011              Guimaracs(a) \[[@B46]\]              Caucasian       HB       PCR-RFLP                 101       188       42           44              15        92        79        17        Y
  2011              Guimaracs(b) \[[@B46]\]              African         HB       PCR-RFLP                 12        188       6            6               0         92        79        17        Y
  **2010**          **Komlosi** \[[@B47]\]               **Caucasian**   **PB**   **PCR-RFLP**             **951**   **939**   **398**      **427**         **126**   **442**   **380**   **117**   **N**
  **2010**          **Karpinski** \[[@B48]\]             **Caucasian**   **HB**   **MSP**                  **186**   **140**   **74**       **97**          **15**    **71**    **55**    **14**    **Y**
  2010              Cui \[[@B49]\]                       Asian           PB       PCR-RFLP                 1829      1700      622          923             284       540       863       297       Y
  2010              Eussen \[[@B50]\]                    Caucasian       PB       MALDI-TOF-MS             1329      2366      567          608             154       1019      1076      271       Y
  2010              Chandy \[[@B51]\]                    Asian           HB       PCR-RFLP                 100       86        74           25              1         66        19        1         Y
  **2010**          **Naghibalhossaini** \[[@B52]\]      **Asian**       **PB**   **MS-PCR**               **151**   **231**   **64**       **80**          **7**     **150**   **68**    **13**    **Y**
  2010              Promthet \[[@B53]\]                  Asian           HB       PCR-RFLP                 130       130       104          26              0         94        31        5         Y
  2010              Yang \[[@B54]\]                      Asian           PB       Sequenom                 141       165       58           61              22        62        75        28        Y
  **2010**          **Fernández - Peralta** \[[@B55]\]   **Caucasian**   **HB**   **PCR-RFLP**             **143**   **103**   **89**       **52**          **2**     **44**    **50**    **9**     **Y**
  2010              Zhu \[[@B56]\]                       Asian           PB       PCR-RFLP                 216       111       88           102             26        50        53        8         Y
  2009              Vogel \[[@B57]\]                     Caucasian       PB       RT-PCR                   689       1793      318          320             51        876       750       167       Y
  2009              Iacopetta \[[@B58]\]                 Mixed           PB       PCR-SSCP                 850       958       382          386             82        428       429       101       Y
  2009              Arreola \[[@B59]\]                   Caucasian       PB       PCR-RFLP                 369       170       124          126             119       59        79        32        Y
  2009              Reeves \[[@B60]\]                    Caucasian       HB       Taqman                   206       211       105          83              18        101       91        19        Y
  **2009**          **Awady** \[[@B61]\]                 **African**     **HB**   **PCR-RFLP**             **35**    **68**    **6**        **23**          **6**     **44**    **20**    **4**     **Y**
  2009              Derwinger \[[@B62]\]                 Caucasian       PB       Taqman                   544       299       273          216             55        167       107       25        Y
  **2008**          **Haghighi** \[[@B63]\]              **Asian**       **HB**   **PCR/pyrosequencing**   **234**   **257**   **117**      **68**          **49**    **94**    **80**    **83**    **N**
  2008              Sharp \[[@B64]\]                     Caucasian       PB       PCR-RFLP                 251       394       117          111             23        170       177       47        Y
  2008              Kury \[[@B65]\]                      Caucasian       PB       Taqman                   1023      1121      435          452             136       457       515       149       Y
  2008              Mokarram \[[@B66]\]                  Asian           HB       MSP                      151       81        64           80              7         40        31        10        Y
  2008              Cao \[[@B67]\]                       Asian           PB       PCR-RFLP                 315       370       109          154             52        121       183       66        Y
  2008              Theodoratou \[[@B68]\]               Caucasian       PB       MassARRAY                999       1010      447          441             111       439       455       116       Y
  2008              Ekolf \[[@B69]\]                     Caucasian       PB       Taqman                   220       414       123          85              12        212       160       42        Y
  2008              Zhang \[[@B70]\]                     Asian           HB       PCR-RFLP                 300       299       97           136             67        91        139       69        Y
  2008              Guerreiro \[[@B71]\]                 Caucasian       HB       Taqman                   196       200       94           76              26        84        107       9         N
  2007              Osian \[[@B72]\]                     Caucasian       HB       PCR-RFLP                 69        67        38           25              6         47        17        3         Y
  2007              Zeybek \[[@B73]\]                    Asian           HB       PCR-RFLP                 52        144       18           27              7         64        65        15        Y
  2007              Lima(a) \[[@B74]\]                   Caucasian       HB       PCR-RFLP                 90        300       36           40              14        143       127       30        Y
  2007              Lima(b) \[[@B74]\]                   African         HB       PCR-RFLP                 10        300       4            5               1         143       127       30        Y
  2007              Chang \[[@B75]\]                     Asian           HB       RT-PCR                   195       195       85           86              24        92        87        16        Y
  2007              Murtaugh \[[@B76]\]                  Mixed           PB       PCR-RFLP                 742       970       357          301             84        466       392       112       N
  **2007**          **Jin** \[[@B77]\]                   **Asian**       **PB**   **Taqman**               **449**   **672**   **182**      **211**         **56**    **211**   **325**   **136**   **Y**
  2007              Curtin \[[@B78]\]                    Mixed           PB       PCR-RFLP                 916       1972      432          402             82        887       858       227       Y
  2007              Hubner \[[@B79]\]                    Caucasian       PB       Taqman                   1685      2691      743          759             183       1173      1192      326       Y
  2006              Koushik \[[@B80]\]                   Caucasian       PB       Taqman                   349       794       166          145             38        355       327       112       N
  2006              Battistelli \[[@B81]\]               Caucasian       HB       PCR-RFLP                 93        100       32           40              21        30        51        19        Y
  2006              Van Guelpen \[[@B82]\]               Caucasian       PB       Taqman                   220       415       123          85              12        212       161       42        Y
  2006              Wang \[[@B83]\]                      Asian           PB       PCR-RFLP                 302       291       257          43              2         255       36        0         Y
  2006              Chen \[[@B84]\]                      Asian           PB       PCR-RFLP                 138       340       52           86              133       207       \-                  
  2005              Matsuo \[[@B85]\]                    Asian           HB       PCR-RFLP                 256       771       106          114             36        289       348       134       Y
  2005              Landi \[[@B86]\]                     Caucasian       HB       RT-PCR                   350       309       128          158             64        109       139       61        Y
  2005              Marchand \[[@B87]\]                  Mixed           PB       PCR-RFLP                 817       2021      394          336             87        987       779       255       N
  2005              Jiang \[[@B88]\]                     Asian           PB       PCR-RFLP                 125       339       51           59              15        134       143       62        N
  2005              Otani \[[@B89]\]                     Asian           HB       MassARRAY                106       222       32           49              25        51        114       57        Y
  2005              Miao \[[@B90]\]                      Asian           PB       PCR-RFLP                 198       420       53           87              58        133       201       86        Y
  2004              Kim \[[@B91]\]                       Asian           HB       PCR-RFLP                 243       225       86           122             35        83        109       33        Y
  2004              Ulvik \[[@B92]\]                     Caucasian       PB       Taqman                   2159      2190      1103         899             157       1092      886       212       Y
  2004              Yin \[[@B93]\]                       Asian           PB       PCR-RFLP                 685       778       270          330             85        278       367       133       Y
  2004              Curtin \[[@B94]\]                    Mixed           HB       PCR-RFLP                 1608      1972      734          724             150       887       858       227       Y
  2003              Pufulete \[[@B95]\]                  Caucasian       HB       PCR-RFLP                 28        76        16           6               6         41        29        6         Y
  2003              Plaschke \[[@B96]\]                  Caucasian       PB       PCR-RFLP                 287       346       133          120             34        149       159       38        Y
  2003              Toffoli \[[@B97]\]                   Caucasian       PB       PCR-RFLP                 276       279       93           145             38        83        140       56        Y
  2003              Heijmans \[[@B98]\]                  Caucasian       PB       PCR-RFLP                 18        793       7            7               4         399       329       65        Y
  2003              Huang \[[@B99]\]                     Asian           HB       PCR-RFLP                 82        82        36           40              6         40        33        9         Y
  2003              Barna \[[@B100]\]                    Caucasian       PB       PCR-RFLP                 101       196       46           48              7         84        97        15        Y
  2002              Keku(a) \[[@B101]\]                  Caucasian       PB       Taqman/PCR-PFLP          308       539       144          140             24        265       223       51        Y
  2002              Keku(b) \[[@B101]\]                  African         PB       Taqman/PCR-PFLP          244       329       198          43              3         264       59        6         Y
  2002              Marchand(a) \[[@B102]\]              Caucasian       PB       PCR-RFLP                 149       171       66           64              19        66        81        24        Y
  2002              Marchand(b) \[[@B102]\]              Asian           PB       PCR-RFLP                 399       485       170          180             49        191       214       80        Y
  2002              Shannon \[[@B103]\]                  Caucasian       PB       PCR-SSCP/RFLP            501       1207      249          197             55        533       560       114       Y
  2002              Matsuo \[[@B104]\]                   Asian           HB       PCR-RFLP                 142       241       39           81              22        81        124       36        Y
  2002              Sachse \[[@B105]\]                   Caucasian       PB       PCR-RFLP                 490       592       238          199             53        271       272       49        Y
  2002              Chen \[[@B106]\]                     Caucasian       PB       PCR-RFLP                 202       326       92           92              18        145       132       49        N
  **2001**          **Ryan**                             **Caucasian**   **PB**   **PCR-RFLP**             **136**   **848**   **49**       **73**          **14**    **439**   **326**   **83**    **Y**
  2000              Slattery \[[@B108]\]                 Caucasian       PB       PCR-RFLP                 232       164       106          107             19        73        71        20        Y
  1999              Slattery \[[@B109]\]                 Mixed           PB       PCR-RFLP                 1467      1821      673          655             139       827       787       207       Y
  1999              Park \[[@B110]\]                     Asian           PB       PCR-RFLP                 200       460       65           107             28        140       246       74        N
  1997              Ma \[[@B111]\]                       Caucasian       PB       PCR-RFLP                 202       326       92           92              18        145       132       49        N
  1996              Chen \[[@B112]\]                     Caucasian       PB       PCR-RFLP                 144       627       67           64              13        280       263       84        Y

These 13 studies in bold were removed afterward because of its heterogeneity and publication bias. Abbreviations: HB: hospital-based control; PB, population-based control; SOC, source of control.

Results of quantitative synthesis {#sec3-2}
---------------------------------

Initially, there was no association between *MTHFR* C677T polymorphism and CRC susceptibility in the dominant model (OR =0.99, 95% CI =0.94--1.05). 0.94--1.05). Nevertheless, for the sake of looking for possible reasons that might lead to such result, we performed heterogeneity analysis and tested publication bias. According to these results, 13 studies were excluded \[[@B29]--[@B31],[@B40],[@B43],[@B47],[@B48],[@B52],[@B55],[@B61],[@B63],[@B77],[@B107]\], the *P*-value was estimated to be 0.824, and the fixed effect model was applied. Ultimately, the results demonstrated that the rs1801133 polymorphism was significantly correlated with the risk of CRC ([Figure 2](#F2){ref-type="fig"}) (dominant model: OR =0.96, 95% CI =0.94--0.99; recessive model: OR =0.90, 95% CI =0.83--0.96; homozygous model: OR =0.88, 95% CI =0.82--0.95; allele model: OR =0.95, 95% CI =0.93--0.98). All detailed results in the present meta-analysis are shown in [Table 2](#T2){ref-type="table"}.

![Forest plots of the association between *MTHFR* C677T polymorphism and CRC susceptibility in dominant model after omitting these 13 studies with heterogeneity and publication bias](bsr-37-bsr20170917-g2){#F2}

###### Meta-analysis results for the included studies of the association between MTHFR rs1801133 polymorphism and risk of CRC

  Variables             Number of studies   Dominant model               Recessive model              Homozygous model      Heterozygous model      Allele model                                                                                                                                          
  --------------------- ------------------- ---------------------------- ---------------------------- --------------------- ----------------------- ------------------- ---------- ----------------------- ------------- ---------- ------------------- ------- ----- ----------------------- ----------- ----------
  ***rs1801133C\>T***                       (CT + TT) compared with CC   TT compared with (CT + CC)   TT compared with CC   CT compared with CC     T compared with C                                                                                                                                     
  All                   78                  **0.96 (0.94--0.99)**        **0.824**                    **0.0**               **0.90 (0.83--0.96)**   **\<**0.001         **49.9**   **0.88 (0.82--0.95)**   **\<**0.001   **42.5**   0.99 (0.96--1.02)   0.950   0.0   **0.95 (0.93--0.98)**   **0.006**   **31.2**
  Ethnicity                                                                                                                                                                                                                                                                                               
    Asian               33                  **0.94 (0.89--1.00)**        **0.418**                    **3.0**               **0.88 (0.77--1.00)**   0.001               **51.2**   **0.86 (0.75--1.00)**   0.001         **49.2**   0.96 (0.91--1.02)   0.933   0.0   **0.94 (0.88--1.00)**   0.002       **47.9**
    Caucasian           36                  0.97 (0.93--1.01)            0.711                        0.0                   0.93 (0.83--1.04)       \<0.001             57.8       0.91 (0.82--1.01)       0.001         47.7       0.99 (0.95--1.03)   0.505   0.0   **0.96 (0.93--1.00)**   **0.079**   **26.2**
    African             3                   0.98 (0.67--1.42)            0.866                        0.0                   0.69 (0.24--2.03)       0.873               0.0        0.72 (0.24--2.15)       0.837         0.0        1.02 (0.69--1.51)   0.852   0.0   0.93 (0.67--1.30)       0.816       0.0
    Mixed               6                   0.98 (0.92--1.04)            0.959                        0.0                   **0.83 (0.75--0.92)**   **0.829**           **0.0**    **0.84 (0.75--0.93)**   **0.830**     **0.0**    1.02 (0.95--1.09)   0.967   0.0   **0.95 (0.90--0.99)**   **0.908**   **0.0**
  Source of control                                                                                                                                                                                                                                                                                       
    HB                  28                  0.96 (0.90--1.03)            0.357                        7.2                   0.97 (0.81--1.16)       \<0.001             59.6       0.96 (0.80--1.15)       \<0.001       54.4       0.98 (0.92--1.04)   0.550   0.0   0.97 (0.90--1.05)       0.007       44.4
    PB                  50                  **0.97 (0.93--1.00)**        **0.911**                    **0.0**               **0.88 (0.81--0.95)**   **0.001**           **43.3**   **0.87 (0.80--0.93)**   **0.012**     **34.1**   0.99 (0.96--1.03)   0.970   0.0   **0.95 (0.92--0.98)**   **0.087**   **22.4**
  Geotyping                                                                                                                                                                                                                                                                                               
    Taqman              14                  0.96 (0.92--1.01)            0.568                        0.0                   **0.86 (0.73--1.00)**   **\<**0.001         **65.0**   **0.85 (0.74--0.99)**   **0.004**     **57.3**   0.99 (0.94--1.05)   0.460   0.0   **0.94 (0.89--0.99)**   **0.085**   **36.4**
    PCR-RFLP            50                  **0.95 (0.91--0.99)**        **0.886**                    **0.0**               **0.90 (0.81--0.99)**   **0.001**           **43.6**   **0.88 (0.79--0.97)**   **0.005**     **37.5**   0.98 (0.94--1.03)   0.992   0.0   **0.95 (0.91--0.99)**   **0.027**   **30.0**
    RT-PCR              4                   1.10 (0.97--1.26)            0.746                        0.0                   1.12 (0.76--1.64)       0.017               70.4       1.15 (0.79--1.66)       0.042         63.4       1.11 (0.96--1.27)   0.771   0.0   1.08 (0.95--1.22)       0.207       34.2

These 13 studies by Ozen et al., Ashmore et al., Delgado-Plasencia et al., Zhu et al., Prasad et al., Komlosi et al., Karpinski et al., Naghibalhossaini et al., Fernández-Peralta et al., Awady et al., Haghighi et al., Jin et al., Ryan et al. were removed \[[@B29], [@B30], [@B31], [@B40], [@B43], [@B47], [@B48], [@B52], [@B55], [@B61], [@B63], [@B77], [@B107]\].

In the subgroup analysis of ethnicity, *MTHFR* C677T polymorphism was found to reduce CRC susceptibility in Asians significantly (dominant model: OR =0.94, 95% CI =0.89--1.00 ([Figure 3](#F3){ref-type="fig"}A); recessive model: OR =0.88, 95% CI =0.77--1.00; homozygous model: OR =0.86, 95% CI =0.75--1.00; allele model: OR =0.92, 95% CI =0.88--1.00). Simultaneously, significantly reduced risks were also found in mixed group (recessive model: OR =0.83, 95% CI =0.75--0.92; homozygous model: OR =0.84, 95% CI =0.75--0.93; allele model: OR =0.95, 95% CI =0.90--0.99). Amongst Caucasians, yet significantly reduced risks were only observed in the allele model (OR =0.96, 95% CI =0.93--1.00). Nevertheless, no significant associations were detected in Africans for all genetic models. When stratified by the source of controls, the positive results were observed in population-based control group (dominant model: OR =0.97, 95% CI =0.93--1.00 ([Figure 3](#F3){ref-type="fig"}B); recessive model: OR =0.88, 95% CI =0.81--0.95; homozygous model: OR =0.87, 95% CI =0.80--0.93; allele model: OR =0.95, 95% CI =0.92--0.98). The similar significant associations were absent from hospital-based group for all the genetic models. The stratified analysis by genotyping methods showed that PCR-RFLP method (dominant model: OR =0.95, 95% CI =0.91--0.99 ([Figure 3](#F3){ref-type="fig"}C); recessive model: OR =0.90, 95% CI =0.81--0.99; homozygous model: OR =0.88, 95% CI =0.79--0.97; allele model: OR =0.95, 95% CI =0.91--0.99) and Taqman method (recessive model: OR =0.86, 95% CI =0.73--1.00; homozygous model: OR =0.85, 95% CI =0.74--0.99; allele model: OR =0.94, 95% CI =0.89--0.99) were significantly correlated with risks of decreased CRC. However, RT-PCR method was not relevant to significant associations for all genetic models. In conclusion, the present meta-analysis suggested that *MTHFR* C677T polymorphism was connected with CRC susceptibility.

![Forest plots of subgroup analysis of the association between *MTHFR* C677T polymorphism and CRC susceptibility in dominant model\
(**A**) Stratified by ethnicity; (**B**) stratified by source of controls; (**C**) stratified by genotyping method.](bsr-37-bsr20170917-g3){#F3}

Test of heterogeneity {#sec3-3}
---------------------

Heterogeneity analysis was performed in this meta-analysis, and heterogeneity was significantly observed between all the included studies in the dominant model (*I*^2^ =62.0%, *P*\<0.001; [Figure 4](#F4){ref-type="fig"}A). In addition, the Galbraith radial plot illustrated heterogeneity obviously. Meanwhile, it specifically pointed out 13 studies that might have led to the obvious heterogeneity and insignificant results of the meta-analysis \[[@B27]--[@B29],[@B38],[@B41],[@B45],[@B46],[@B50],[@B53],[@B59],[@B61],[@B75],[@B105]\]. After excluding 13 studies, the heterogeneity decreased significantly (*I*^2^ =0.0%, *P*=0.789; [Figure 4](#F4){ref-type="fig"}B) in the present meta-analysis.

![Galbraith plot of the association between *MTHFR* C677T polymorphism and CRC susceptibility in dominant model\
(**A**) Before removing these 13 studies. (**B**) After the exclusion of these studies.](bsr-37-bsr20170917-g4){#F4}

Publication bias {#sec3-4}
----------------

The Begg's funnel plot and Egger's test were performed to assess the publication bias. Initially, the Begg's funnel plot was asymmetrical obviously with all the included studies and it suggested a potential publication bias (Begg's test: *P*=0.103; Egger's test: *P*=0.058; [Figure 5](#F5){ref-type="fig"}A). After the removal of 13 studies mentioned above \[[@B27]--[@B29],[@B38],[@B41],[@B45],[@B46],[@B50],[@B53],[@B59],[@B61],[@B75],[@B105]\], the plots seemed to have a symmetrical distribution in the funnel plot and then Egger's test was used to provide statistical evidence (Begg's test: *P*=0.369; Egger's test: *P*=0.136; [Figure 5](#F5){ref-type="fig"}B). No significant publication bias was observed in the present studies.

![Begg's funnel plot of publication bias test\
(**A**) Before omitting these 13 studies. (**B**) After the exclusion of these studies.](bsr-37-bsr20170917-g5){#F5}

Sensitivity analysis {#sec3-5}
--------------------

In order to distinguish the impact of each study on the pooled ORs, we conducted one-way sensitivity analysis. Each time one study was omitted, meta-analysis was repeated and the statistical significance of the results was not changed. Therefore, the results confirmed that the present meta-analysis was relatively stable and reliable.

Discussion {#sec4}
==========

*MTHFR* is a key enzyme in the folate metabolism and may play a role in the CRC carcinogenesis. It is an essential enzyme in the catalytic reaction that converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate. On one hand, 5,10-methylenetetrahydrofolate takes part in the thymidylate synthesis. On the other hand, 5-methyltetrahydrofolate promotes methionine synthesis and SAM-mediated methylations. In brief, *MTHFR* has an influence on DNA synthesis, methylation, and repair \[[@B113]\]. The *MTHFR* polymorphisms result in the decreased enzyme activity and then low levels of plasma folate and high homocysteine come to light. Folate is one of water-soluble B vitamins that takes part in various biochemical reactions with its activity to provide or accept one-carbon units \[[@B13]\]. Folate deficiency is likely to contribute to the development of CRC, and several mechanisms may explain how it leads to CRC, including DNA strand breaks, abnormal DNA methylation, and impaired DNA repair \[[@B114]\].

Several polymorphisms have been reported about the *MTHFR* gene coding relevant enzyme, and *MTHFR* C677T polymorphism is the most common one. Heretofore, various studies conducted to detect such association and obtained inconsistent results. Chen et al. \[[@B112]\], first reported that *MTHFR* variant homozygous (TT) genotype was closely linked to reduced incidence of CRC with low consumption of alcohol. In the next few years, similar results were replicated by several other studies \[[@B109]--[@B111]\]. However, another study of a homogeneous northern European population obtained different conclusions that *MTHFR* CT heterozygote had a significantly increased risk of developing CRC and no increased cancer risk was observed in TT homozygotes \[[@B107]\]. In addition, a hospital-based case--control study conducted by Matsuo et al. \[[@B104]\] found no significant relativity between *MTHFR* C677T and the risks of CRC. Owing to the difference in study design and the sample size, the different ethnicity, and the diverse stratification, these controversial results were found in published studies. Hence, meta-analysis is essential to be carried out by combining all studies that meet the requirements to get more precise conclusions.

In recent years, there were several meta-analyses performed to elucidate the association of *MTHFR* C677T polymorphism and the susceptibility to CRC before \[[@B26],[@B115]--[@B118]\]. Compared with them, this meta-analysis included the most eligible reported studies with the largest sample size and had no restrictions in ethnicity. Since the quality of included documents were disequilibrium, our initial analysis achieved no significant results with all eligible studies. In order to obtain more reliable results, the final conclusion were obtained excluding 13 studies in accordance with the analysis of heterogeneity and publication bias. In this meta-analysis, the pooled conclusions revealed that rs1801133 polymorphism significantly reduced the risk of CRC in the dominant model. The findings agreed with the overwhelming majority results reported by the published studies.

When stratified by ethnicity, there was a significant association with reduced risks of CRC in Asians. The result was consistent with the two previous meta-analysis based on the Asians \[[@B116],[@B117]\]. Zhong et al. \[[@B118]\], carried out a meta-analysis obtaining similar results in East Asians and further subgroup analyses by country identified such association in Korea and Japan. Nevertheless, the recent meta-analysis failed to identify that rs1801133 polymorphism was connected with CRC susceptibility in Iranian population \[[@B26]\]. By means of stratified analysis based on the source of controls and genotyping methods, the positive results were observed in population-based control group and PCR-RFLP method. In general, the source of controls included healthy individuals and patients without CRC. Since the risks of CRC varies amongst individuals over a few years, it might have an impact on the results of relevant studies and make them unreliable. Therefore, inclusion criteria should be improved and studies with large sample sizes should be accepted. In the subgroup of genotyping method, there were nine methods applied for genotyping such as PCR-RFLP, RT-PCR, PCR-SSCP, MS-PCR, MSP, MALDI-TOF-MS, Taqman, MassARRAY, and Sequenom in the including studies. Specific methods and steps were described in each article. Amongst these 87 studies, the majority method was PCR-RFLP. Different methods have their own merits, and when all included studies used the same method, the final results would be more reliable.

In the present meta-analysis, we had obtained weak associations significantly with a large sample size. However, the potential limitations of the meta-analysis should be acknowledged. First, this meta-analysis was based on unadjusted effect estimates and 95% CI, and the influence of multiple cofactors such as age, gender, diet habits including intake of alcohol and consumption of cigarette, the level of folate, and the other environmental factors should be taken into consideration. Second, because of incomplete data of some genotypes, only the dominant model was analyzed in all the included studies. Third, we did not perform stratification analysis by serum folate levels, locations of the tumor and so on, which might result in confounding bias. In addition, after excluding 13 studies according to the analysis of heterogeneity and publication bias, the heterogeneity decreased significantly and the publication bias seemed to disappear. However, the selection bias existed because all the studies were published. Furthermore, the gene--gene and gene--environment interactions were not mentioned in this meta-analysis. In addition, the potential roles of the gene polymorphism which were hidden or magnified by other interactions were omitted.

Conclusion {#sec5}
==========

In summary, the present meta-analysis revealed that there was a significant association between *MTHFR* C677T polymorphism and susceptibility to CRC. Simultaneously, the TT genotype of *MTHFR* C677T polymorphism could reduce the risk of CRC. In addition, the associated risk of CRC was also reduced in Asians and those studies with population-based controls and used the PCR-RFLP method. Therefore, detection of the *MTHFR* C677T polymorphism might be used as markers for CRC prediction and treatment selection.

Competing interests {#sec6}
===================

The authors declare that there are no competing interests associated with the manuscript.

Funding {#sec7}
=======

This work has been supported by the Natural Science Funding of Jiangsu Province \[grant number BK20141492\]; and the '333 Project' of Jiangsu Province \[grant number BRA2016517\].

Author contribution {#sec8}
===================

Y.G., H.Y., and Z.Q. were responsible for conception and design. Y.G., H.Y., and F.W. provided the administrative support. S.S., Z.Q., and L.L. were responsible for the collection and assembly of data. P.L., X.H., and X.C. were responsible for data analysis and interpretation. L.X., Z.Q., and F.W. were responsible for manuscript writing. All the authors approved the final manuscript.

CI

:   confidence interval

CRC

:   colorectal cancer

HWE

:   Hardy--Weinberg equilibrium

MSP

:   mutagenically separated PCR

MS-PCR

:   methylation-specific PCR

MTHFR

:   methylenetetrahydrofolate reductase

OR

:   odds ratio

PCR-RFLP

:   PCR-restriction fragment length polymorphism

PCR-SSCP

:   PCR-single strand conformation polymorphism

PRISMA-P

:   preferred reporting items for systematic review and meta-analysis protocol

RT-PCR

:   real-time PCR

SAM

:   S-adenosylmethionine

[^1]: Lingyan Xu, Zhiqiang Qin and Feng Wang contributed equally to this work.
